Home Medical OncologyQuestion

Would you offer adjuvant avapritinib or imatinib for a high-risk, PDGFR D842V-mutated GIST after resection?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Which patient characteristics or clinical factors guide the decision to use Doxorubicin and Trabectedin as first-line treatment for metastatic or unresectable leiomyosarcoma?

How would you treat an unresectable epithelioid angiosarcoma invading the cavernous sinus, wrapping around the carotid artery?

How do you approach adjuvant chemotherapy in an adult with localized osteosarcoma who demonstrates 50–90% tumor necrosis on surgical pathology following neoadjuvant doxorubicin and cisplatin?

How would you treat a patient with concurrent diagnoses of symptomatic multiple myeloma and a newly diagnosed upper extremity undifferentiated pleomorphic sarcoma?

How do you approach a patient with indolent, small-volume, but slowly progressive lung mets from sarcoma?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.